KRAS and colorectal carcinoma: As mentioned above, the combination of β-elemene and cetuximab, an ferroptosis inducer, can induce ferroptosis in the colorectal cancer cell with KRAS mutation, thus relieving the drug resistance caused by cetuximab in CRC treatment (Chen et al., 2020a).